Evidence map›Paper›PMID 31165304›Full record

ArticleThe AAPS journal2019

Correction to: A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART®.

Alison Betts, Nahor Haddish-Berhane, Dhaval K Shah, Piet H van der Graaf, Frank Barletta, Lindsay King, Tracey Clark, Cris Kamperschroer, Adam Root, Andrea Hooper and 1 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in The AAPS journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Physiological Considerations for ModelingFrontiers in pharmacology · 2022
    Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Alison BettsDepartment of Biomedicine Design, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts, 02139, USA. alison.betts@pfizer.com.
Nahor Haddish-BerhaneJanssen Research & Development, LLC, Spring House, Pennsylvania, 19477, USA.
Dhaval K ShahDepartment of Pharmaceutical Sciences, 455 Kapoor Hall, University at Buffalo, The State University of New York, Buffalo, New York, 14214-8033, USA.
Piet H van der GraafDivision of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, 2300 RA, Leiden, The Netherlands.
Frank BarlettaOncology Research Unit, Pfizer Inc., 401 N Middletown Rd., Pearl River, New York, 10965, USA.
Lindsay KingDepartment of Biomedicine Design, Pfizer Inc., 1 Burtt Road, Andover, Massachusetts, USA.
Tracey ClarkEstablished Med Business, Pfizer Inc., Eastern Point Rd, Groton, Connecticut, 06340, USA.
Cris KamperschroerDepartment of Immunotoxicology, Pfizer Inc., 558 Eastern Point Road, Groton, Connecticut, 06340, USA.
Adam RootDepartment of Biomedicine Design, Pfizer Inc., 610 Main Street, Cambridge, Massachusetts, 02139, USA.
Andrea HooperOncology Research Unit, Pfizer Inc., 401 N Middletown Rd., Pearl River, New York, 10965, USA.
Xiaoying ChenDepartment of Clinical Pharmacology, Pfizer Inc., 10555 Science Center Dr., San Diego, California, 92121, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Typesetting error occurred and Figure 1a and Figure 1b were altered during the uploading process. The original article has been corrected.

Identifiers

PMID31165304
PMCPMC6828401

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.